罗氟司特怎么服用？

Roflumilast was developed by the German company Altana in 1993 and is now a product of the Swiss Nycomed Pharma GmbH. In 2009, Swiss Nycomed completed phase III clinical trials of roflumilast and submitted a marketing application in Europe. The EU approved the marketing of roflumilast (Daxas) on July 6, 2010. Later, Nycomed signed a cooperation agreement with ForestLab. ForestLab invested US$600 million to obtain the rights to sell Daxas in the United States, and was responsible for the application, promotion and sales of the FDA review in the United States. Nycomed will retain sales rights for the drug in Europe and other parts of the world.

How to take roflumilast? Roflumilast is administered orally and is metabolized to N-oxide by cytochrome oxidase P450 (CYP) 3A4 and CYP1A2 enzymes after entering the body. The activity of roflumilast N-oxide is only 2 to 3 times weaker than that of roflumilast, and it also has high PDE-4 selectivity. About 90% of the PDE-4 inhibitory effect in the human body is produced by roflumilast N-oxide, and the other 10% is produced by the prototype of roflumilast. Healthy people take 500 μg of roflumilast orally (once a day). After 24 hours, the free plasma concentration of roflumilast N-oxide is about 1 to 2 nmol·L-1, and its plasma protein binding capacity is about 97%. Smoking has a minor effect on the pharmacokinetics of roflumilast.

It is not currently listed in China, so it is not eligible for medical insurance. In other words, if patients want to purchase the drug, they must go abroad to purchase it. Traveling abroad to buy medicines is a long journey and requires a lot of manpower and material resources. Coupled with the huge medical expenses, many patient families are overwhelmed. However, according to Medical Companion Travel, 500μg*90 tablets of roflumilast costs approximately $2,850 per box. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about roflumilast, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.